Tri Locum Partners LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Tri Locum Partners LP reported 20 stock positions worth $417.4 million. Its top holding was Pfizer (PFE) at 12.0% of the portfolio, followed by Teva Pharmaceutical-SP ADR (TEVA, 11.9%) and Natera (NTRA, 9.7%). Compared with Q2 2024, it opened 3 new positions, sold out of 8, added to 10 and reduced 6. The biggest buy was Pfizer (PFE, shares +190%) and the biggest sale an exit from Ascendis Pharma A/S (ASND).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $417.4M (Q3 2024)
- SEC Filing
- 0001826434-24-000009 ↗ filed Nov 14, 2024
Holdings Value
Holdings 20 stocks · $417.4M
| PFE Pfizer Inc. | 12.01% | 1,732,935 | $50.2M | Add +190.3% |
| TEVA Teva Pharmaceutical-SP ADR | 11.90% | 2,755,737 | $49.7M | Add +8.1% |
| NTRA Natera Inc. | 9.65% | 317,439 | $40.3M | Add +37.7% |
| STVN Stevanato Group SPA | 8.95% | 1,867,938 | $37.4M | Add +230.4% |
| ARGX Argenx SE - ADR | 8.11% | 62,474 | $33.9M | Reduce -16.2% |
| INSP Inspire Medical Systems Inc. | 7.66% | 151,429 | $32.0M | Add +13.6% |
| PCVX Vaxcyte Inc. | 7.44% | 271,922 | $31.1M | Add +139.9% |
| AVDL Avadel Pharmaceuticals Ltd. | 5.22% | 1,660,955 | $21.8M | New |
| UTHR United Therapeutics Corp. | 4.72% | 54,926 | $19.7M | Add +9.6% |
| LEGN Legend Biotech Corp.-ADR | 4.23% | 362,270 | $17.7M | Add +1.6% |
| VRNA Verona Pharma Ltd. | 4.09% | 593,980 | $17.1M | New |
| INSM Insmed Inc. | 2.52% | 143,920 | $10.5M | Reduce -54.5% |
| BHVN Biohaven Ltd. | 2.31% | 193,195 | $9.7M | New |
| MRUS Merus NV | 2.30% | 192,157 | $9.6M | Reduce -42.7% |
| MIND MEDICINE MINDMED INC | 2.27% | 1,662,953 | $9.5M | Add +335.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.20% | 43,287 | $9.2M | Reduce -33.8% |
| AXSM Axsome Therapeutics Inc. | 1.97% | 91,721 | $8.2M | Reduce -70.1% |
| NVO Novo-Nordisk A/S-Spons ADR | 1.92% | 67,257 | $8.0M | Add +5.4% |
| KRRO Korro Bio Inc. | 0.51% | 64,014 | $2.1M | Reduce -10.4% |
| FEMY Femasys Inc. | 0.01% | 30,606 | $34K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −7.85 |
| AMGN Amgen Inc. | Sold out | 0.00% | −6.50 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −4.65 |
| AXSM Axsome Therapeutics Inc. | Reduce -70.1% | 1.97% | −4.26 |
| AVDL Avadel Pharmaceuticals plc | Sold out | 0.00% | −4.23 |
| INSM Insmed Inc. | Reduce -54.5% | 2.52% | −2.84 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.76 |
| MRUS Merus NV | Reduce -42.7% | 2.30% | −2.72 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -33.8% | 2.20% | −2.43 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −1.01 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −0.89 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −0.79 |
| KRRO Korro Bio Inc. | Reduce -10.4% | 0.51% | −0.10 |
| ARGX Argenx SE - ADR | Reduce -16.2% | 8.11% | +0.01 |
Portfolio Buys Q2 2024 → Q3 2024
| PFE Pfizer Inc. | Add +190.3% | 12.01% | +7.79 |
| STVN Stevanato Group SPA | Add +230.4% | 8.95% | +6.33 |
| PCVX Vaxcyte Inc. | Add +139.9% | 7.44% | +5.28 |
| AVDL Avadel Pharmaceuticals Ltd. | New | 5.22% | +5.22 |
| VRNA Verona Pharma Ltd. | New | 4.09% | +4.09 |
| NTRA Natera Inc. | Add +37.7% | 9.65% | +3.34 |
| INSP Inspire Medical Systems Inc. | Add +13.6% | 7.66% | +3.15 |
| BHVN Biohaven Ltd. | New | 2.31% | +2.31 |
| MIND MEDICINE MINDMED INC | Add +335.3% | 2.27% | +1.57 |
| TEVA Teva Pharmaceutical-SP ADR | Add +8.1% | 11.90% | +1.42 |
| UTHR United Therapeutics Corp. | Add +9.6% | 4.72% | +0.68 |
| LEGN Legend Biotech Corp.-ADR | Add +1.6% | 4.23% | +0.24 |
| NVO Novo-Nordisk A/S-Spons ADR | Add +5.4% | 1.92% | −0.38 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |